References
- R Cairns, I Papandreou, and N Denko. (2006). Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. Mol Cancer Res 4:61–70.
- SA Cannistra, C Ottensmeier, J Niloff, and et al (1995). Expression and function of beta1 and alphavbeta3 integrins in ovarian cancer. Gynecol Oncol 58:216–225.
- F Carreiras, S Cruet, C Staedel, and et al (1999). Human ovarian adenocarcinoma cells synthesize vitronectin and use it to organize their adhesion. Gynecol Oncol 72:312–322.
- P Crosasso, M Ceruti, P Brusa, and et al (2000). Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release 63:19–30.
- RE Eliaz, and FC Szoka. (2001). Liposome-encapsulated doxorubicin targeted to CD44: A strategy to kill CD44-overexpressing tumor cells. Cancer Res 61:2592–2601.
- RO Hynes. (1987). Integrins: A family of cell surface receptors. Cell 48:549–554.
- RO Hynes. (1992). Integrins: Versatility, modulation, and signaling in cell adhesion. Cell 9:11–25.
- RO Hynes. (1999). Cell adhesion: Old and new questions. Trends Cell Biol 9:M33–M37.
- A Ito, K Ino, T Kobayashi, and et al (2005). The effect of RGD peptide-conjugated magnetite cationic liposomes on cell growth and cell sheet harvesting. Biomaterials 26:6185–6193.
- SC Kim, DW Kim, YH Shim, and et al (2001). In vivo evaluation of polymeric micellar paclitaxel formulation: Toxicity and efficacy. J Control Release 72:191–202.
- R Krishna, and LD Mayer. (1997). Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors. Cancer Res 57:5246–5253.
- EF Plow, TA Haas, L Zhang, and et al (2000). Ligand binding to integrins. J Biol Chem 275:21785–21788.
- RA Quirk, WC Chan, MC Davies, and et al (2001). Poly(-lysine)-GRGDS as a biomimetic surface modifier for poly(lactic acid). Biomaterials 22:865–872.
- EK Rowinsky, and RC Donehower. (1995). Paclitaxel (taxol). N Engl J Med 332:1004–1014.
- A Sharma, E Mayhew, and RM Straubinger. (1993). Antitumor effect of taxol-containing liposomes in a taxol-resistant murine tumor model. Cancer Res 53:5877–5881.
- A Sharma, and RM Straubinger. (1994). Novel taxol formulations: Preparation and characterization of taxol-containing liposomes. Pharm Res 11:889–896.
- SI Shen, PR Kotamraj, S Bhattacharya, and et al (2007). Synthesis and characterization of RGD-fatty acid amphiphilic micelles as targeted delivery carriers for anticancer agents. J Drug Target 15:51–58.
- JW Singer. (2005). Paclitaxel poliglumex (XYOTAX(TM), CT-2103): A macromolecular taxane. J Control Release 109:120–126.
- AK Singla, A Garg, and D Aggarwal. (2002). Paclitaxel and its formulations. Int J Pharm 235:179–192.
- K Temming, RM Schiffelers, G Molema, and et al (2005). RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature. Drug Resist Update 8:381–402.
- JA Varner, and DA Cheresh. (1996). Integrins and cancer. Curr Opin Cell Biol 8:724–730.
- XB Xiong, Y Huang, WL Lu, and et al (2005a). Enhanced intracellular delivery and improved antitumor efficacy of doxorubicin by sterically stabilized liposomes modified with a synthetic RGD mimetic. J Control Release 107:262–275.
- XB Xiong, Y Huang, WL Lu, and et al (2005b). Enhanced intracellular uptake of sterically stabilized liposomal Doxorubicin in vitro resulting in improved antitumor activity in vivo. Pharm Res 22:933–939.
- XB Xiong, Y Huang, WL Lu, and et al (2005c). Intracellular delivery of doxorubicin with RGD-modified sterically stabilized liposomes for an improved antitumor efficacy: In vitro and in vivo. J Pharm Sci 94:1782–1793.
- Z Xiong, Z Cheng, X Zhang, and et al (2006). Imaging chemically modified adenovirus for targeting tumors expressing integrin alphavbeta3 in living mice with mutant herpes simplex virus type 1 thymidine kinase PET reporter gene. J Nucl Med 47:130–139.
- F Yuan, M Leunig, SK Huang, Papahadjopoulos, RK Jain, and et al (1994). Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 54:3352–3356.
- JA Zhang, G Anyarambhatla, L Ma, and et al (2005). Development and characterization of a novel Cremophor EL free liposome-based paclitaxel (LEP-ETU) formulation. Eur J Pharm Biopharm 59:177–187.